ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "non-radiographic and tumor necrosis factor (TNF)"

  • Abstract Number: 1507 • ACR/ARHP Annual Meeting 2017

    Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis

    Robert B.M. Landewé1, Joachim Sieper2, Atul A. Deodhar3, Helena Marzo-Ortega4, Robert G. Lambert5, Mei Li6, Xin Wang6 and Jaclyn K. Anderson6, 1University of Amsterdam, Amsterdam, Netherlands, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4NIHR LBRC, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom, 5University of Alberta, Edmonton, AB, Canada, 6AbbVie Inc., North Chicago, IL

    Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…
  • Abstract Number: 1787 • ACR/ARHP Annual Meeting 2017

    Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

    Robert B.M. Landewé1, Joachim Sieper2, Philip J Mease3, Robert D Inman4, Xin Wang5, Mei Li5, Aileen L. Pangan5 and Jaclyn K. Anderson5, 1University of Amsterdam, Amsterdam, Netherlands, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Swedish Medical Center and University of Washington, Seattle, WA, 4Department of Immunology, University of Toronto, Toronto, ON, Canada, 5AbbVie Inc., North Chicago, IL

    Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…
  • Abstract Number: 2501 • ACR/ARHP Annual Meeting 2017

    Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare

    Robert B.M. Landewé1, Joachim Sieper2, Uta Kiltz3, Xin Wang4, Mei Li4 and Jaclyn K. Anderson4, 1University of Amsterdam, Amsterdam, Netherlands, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: It has been recommended that the lower limit of high-sensitivity CRP (hsCRP) be restricted to 2 in the Ankylosing Spondylitis Disease Activity Score (ASDAS)…
  • Abstract Number: 2803 • ACR/ARHP Annual Meeting 2017

    Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment

    Joachim Sieper1, Robert B.M. Landewé2, Marina N. Magrey3, Jaclyn K. Anderson4, Sheng Zhong4, Xin Wang4 and Apinya Lertratanakul4, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2University of Amsterdam, Amsterdam, Netherlands, 3Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, 4AbbVie Inc., North Chicago, IL

    Background/Purpose:  Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…
  • Abstract Number: 2938 • ACR/ARHP Annual Meeting 2014

    A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis

    J Sieper1, D van der Heijde2, M Dougados3, Walter P. Maksymowych4, J Boice5, G Bergman5, S Curtis5, A Tzontcheva5, S Huyck5 and HH Weng5, 1University Clinic Benjamin Franklin, Berlin, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Paris-Descartes University, Paris, France, 4Department of Medicine, University of Alberta, Alberta, AK, 5Merck & Co., Inc., Whitehouse Station, NJ

    Background/Purpose Axial spondyloarthritis (axSpA), including ankylosing spondylitis and nonradiographic axial SpA (nr-axSpA), is a chronic inflammatory disease marked by back pain and progressive spinal stiffness.…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology